Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDianthus Therapeutics Inc.

Dianthus Therapeutics Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
89.44 USD 3.41 ( 3.96%)
Last update at 2026-11-09T15:42:00Z
VOLUME
61202
Market Cap
4908.56M

Momentum Score

…

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
84.41
Low
89.52
High
52 Week Price Range
16.64
Low
96.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Dianthus Therapeutics Inc. is a Nasdaq-listed biotechnology company; public disclosures and its website provide limited detail about its therapeutic pipeline and operations. Long-term growth may depend on advancing clinical or preclinical programs, securing partnerships and funding, and demonstrating regulatory progress, which could support upside for investors if early-stage programs validate their hypotheses.

Key risks include clinical and regulatory failure, funding shortfalls and dilution, limited public information and transparency, and execution challenges common to small biotech companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
86.03
Dividend Yield
-
Revenue TTM
2.04M
Revenue Per Share
0.05
Gross Profit TTM
2.04M
Debt / Equity
0.00
ROE
-38.38%
Net Debt
-49.70M
ROCE
-35.57%
Diluted EPS TTM
-4.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -162.34M -84.97M -43.55M -28.48M -13.11M
Net income -162.34M -84.97M -43.55M -28.48M -13.11M
Selling general administrative 34.33M 24.99M 18.16M 6.74M 1.96M
Selling and marketing expenses - - 0.35M - -
Gross profit 2.04M 6.24M 2.83M 6.42M 1.48M
Reconciled depreciation 0.43M 0.41M 0.30M 0.15M 0.00M
Ebit - -101.86M -48.17M -29.84M -15.08M
Ebitda -177.93M -101.45M -47.82M -29.69M -13.06M
Depreciation and amortization - 0.41M 0.35M 0.15M 2.02M
Operating income -177.93M -101.86M -48.17M -29.70M -13.09M
Other operating expenses 179.97M 108.10M 51.00M 36.12M 14.56M
Interest expense - - - - 3.56M
Interest income 16.12M 17.36M 2.96M 1.15M 0.00M
Net interest income 16.12M 17.36M 2.96M 1.15M 0.00M
Income tax expense - - 0.19M -1.28M -2.00M
Total revenue 2.04M 6.24M 2.83M 6.42M 1.48M
Total operating expenses 179.97M 108.10M 51.00M 36.12M 14.56M
Cost of revenue - 0.41M 0.35M - -
Total other income expense net 15.60M 16.89M 4.62M 0.08M -0.03M
Net income from continuing ops -162.34M -84.97M -43.11M -28.48M -13.11M
Net income applicable to common shares - - - -28.48M -13.11M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 530.92M 374.01M 179.41M 83.11M 9.45M
Other current assets 5.04M 4.86M 3.25M 0.05M 0.01M
Total liab 37.52M 21.53M 10.54M 127.48M 26.70M
Total stockholder equity 493.40M 352.48M 168.87M -44.37M -17.25M
Other current liab 19.45M 13.07M 6.50M 6.61M 3.99M
Common stock 0.04M 0.03M 0.01M 0.06M 0.06M
Capital stock 0.04M 0.03M 0.01M 0.00M 0.00M
Retained earnings -336.73M -174.39M -89.42M -45.87M -17.39M
Other liab - - - 0.79M -
Other assets - - - 0.12M 0.03M
Cash 51.09M 22.79M 132.32M 15.37M 7.64M
Total current liabilities 30.73M 18.45M 9.63M 8.22M 5.35M
Current deferred revenue 1.19M 0.48M 0.10M 0.10M -
Net debt -49.70M -21.30M -131.74M -14.58M -7.64M
Short term debt 0.37M 0.32M 0.42M 0.35M -
Short long term debt total 1.39M 1.49M 0.58M 0.79M -
Other stockholder equity 829.60M 526.73M 78.83M 1.60M 0.11M
Property plant equipment - - - 0.96M 0.03M
Total current assets 409.44M 280.90M 177.45M 82.03M 9.39M
Long term investments 110.14M 81.73M - - -
Net tangible assets - - - -44.37M -17.25M
Short term investments 353.21M 252.45M 41.39M 60.12M 45.28M
Net receivables 0.10M 0.81M 0.48M 5.64M 1.48M
Inventory - - - 0.85M 0.26M
Accounts payable 9.72M 4.58M 2.61M 1.17M 1.36M
Accumulated other comprehensive income 0.49M 0.11M 0.05M -0.16M -0.03M
Non currrent assets other 9.72M 9.63M 1.09M 0.12M 0.03M
Non current assets total 121.48M 93.10M 1.95M 1.08M 0.06M
Capital lease obligations 1.39M 1.49M 0.58M 0.79M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -122.62M -286.81M 15.82M -59.82M -0.03M
Change to liabilities - - - 3.17M 4.92M
Total cashflows from investing activities -122.83M -286.81M 20.25M -59.82M -0.03M
Net borrowings - 0.00M 0.00M - -
Total cash from financing activities 280.12M 255.62M 133.57M 96.68M 14.91M
Change to operating activities - - - -4.89M -0.77M
Net income -162.34M -84.97M -43.55M -28.48M -13.11M
Change in cash 28.23M -109.37M 116.97M 7.79M 4.97M
Begin period cash flow 23.02M 132.39M 15.43M 7.64M 2.66M
End period cash flow 51.25M 23.02M 132.39M 15.43M 7.64M
Total cash from operating activities -129.06M -78.18M -36.86M -29.07M -9.90M
Issuance of capital stock 272.27M 269.20M 72.00M 100.00M 15.00M
Depreciation 0.43M 0.41M 0.35M 0.15M 2.02M
Change to account receivables 0.76M 0.00M 5.16M 0.07M -1.01M
Sale purchase of stock 0.32M - - - -
Other cashflows from financing activities 280.12M -13.57M 61.57M 93.77M 14.91M
Change to netincome - - - 0.91M 0.06M
Capital expenditures 0.21M 0.10M 0.11M 0.14M 0.03M
Change in working capital 16.73M -0.35M 4.86M -1.65M 3.14M
Stock based compensation 22.79M 12.89M 2.90M 1.52M 0.06M
Other non cash items -6.67M -6.17M -0.76M -0.61M -2.02M
Free cash flow -129.27M -78.28M -36.97M -29.21M -9.94M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DNTH
Dianthus Therapeutics Inc.		 3.41
3.96%		 89.44 - - 2410.88 9.95 2212.99 -7.35
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Dianthus Therapeutics Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

7 Times Square, New York, NY, United States, 10036

929 999 4055

https://dianthustx.com

92

Name Title Year Born
Mr. Marino Garcia M.B.A. President, CEO, Secretary & Director 1966
Mr. Ryan Savitz CFO and Chief Business Officer & Treasurer NA
Mr. Edward G. Carr Chief Accounting Officer 1969
Mr. Judson Taylor Head of Technical Operations NA
Dr. Jeffrey Stavenhagen Ph.D. Chief Scientific Officer NA
Ms. Jennifer Davis Ruff VP and Head of Investor Relations & Corporate Affairs. NA
Mr. Adam M. Veness Esq. General Counsel 1986
Ms. Kristina Maximenko Chief People Officer NA
Mr. Simrat Randhawa M.B.A., M.D. Chief Medical Officer NA
Ms. Rashieda Gluck Head of Clinical Development Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…